Follow on Google News News By Tag * Molecular Diagnostics (MDx) * Infectious Disease Testing * Rare Diseases * Clinical Chemistry * Clinical Microbiology * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | ‘The molecular diagnostics (MDX) world market will reach $6.13bn in 2014’By: Visiongain The molecular diagnostics market is growing at a far higher rate as compared to the rest of the IVD market. Drivers of growth in the MDx market over the forecast period include oncology testing, hospital acquired infection testing and HPV testing. Amy To, a pharmaceutical and medical devices analyst at visiongain explains: “The fastest growing segment of the MDx market will be oncology testing, where the tests can be used to determine a patient’s susceptibility to certain cancers and to evaluate their response to certain cancer drugs. In these instances, the high initial cost of MDx tests are more than offset by their clinical value. These tests can maximise the likelihood of cancer treatment efficiency and minimise the risk of adverse side effects. However, despite their potential to reduce the burden of healthcare costs, the MDx market is still restrained by reimbursement challenges. Healthcare services have generally been slow to adopt MDx tests when there have been cheaper diagnostic technologies such as serology and culture available. Moreover, the billing of diagnostic services is complex in the U.S with many MDx test claims being paid incorrectly. There have been concerted efforts to make the molecular pathology code for labelling MDx tests more consistent in order to simplify the billing of services. As the regulatory and reimbursement framework for molecular tests catches up with the pace of innovation, there will be more reassurance for investors that this will be a highly lucrative sector of the medical devices market.” Growth in Western Europe and the U.S will be constrained over the forecast period owing to the increasing consolidation of diagnostic laboratories. China will be the fastest growing country over the forecast period, driven by heavy healthcare investment, increasing patient healthcare access and the rising incidence of cancer in the country. Visiongain’s new 173-page report provides revenue forecasts to 2024 for the global molecular diagnostics market, its submarkets by application type and leading national markets. It forecasts sales in the US, Japan, Europe (EU5: Germany, France, Italy, Spain, UK and the rest of Europe), China, India, Russia, Brazil, South Korea, Mexico and the Rest of the World. It also profiles 7 leading MDx companies, including their MDx division financial performance, product portfolio and recent commercial activity. It also includes an interview transcript with an industry expert regarding the current developments and the drivers of growth in the MDx market. The Molecular Diagnostics (MDx) Market Forecast 2014-2024: Opportunities for Leading Companies adds to visiongain’s range of analytical reports on industries and markets in healthcare. For sample pages and further information concerning the visiongain report The Molecular Diagnostics (MDx) Market Forecast 2014-2024: Opportunities for Leading Companies please visit https://www.visiongain.com/ For an executive summary please contact: Email: Sara Peerun on sara.peerun@ Tel: +44 (0) 20 7336 6100 Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@ About visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first portofcall for the business professional who needs independent, high quality, original analyses to inform their strategic decisions. End
Account Phone Number Disclaimer Report Abuse
|
|